Stocktwits on MSN
IBRX stock is back: Anktiva now targets severe pneumonia after clearing key checkpoint in bladder cancer trial
The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results